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Is the nephritogenic antigen in post-streptococcal glomeru-
lonephritis pyrogenic exotoxin B (SPE B) or GAPDH?
Background. Acute glomerulonephritis can follow infection
by group A streptococci. An immune-complex pathogenesis is
accepted, but the causative antigen(s) is still controversial. In
recent years, 2 streptococcal antigens, the cationic cysteine pro-
teinase exotoxin B (SPE B) and the plasmin receptor, a glyc-
eraldehyde phosphate dehydrogenase (Plr, GAPDH) have at-
tracted attention because: (1) they were localized in glomeruli
in patients with acute post-streptococcal glomerulonephritis
(APSGN); and (2) serum antibody to these antigens was as-
sociated with nephritogenic streptococcal infections.
To date, putative nephritogens were always tested inde-
pendently. Here, the relevance of SPE B and GAPDH was
evaluated in the same renal biopsies and serum samples of well-
defined APSGN patients.
Methods. Renal biopsies (17 patients) and serum samples
(53 patients) with APSGN and appropriate controls were ex-
amined. Immunofluorescent staining of frozen sections was
performed using specific antibodies to SPE B and GAPDH.
Serum antibodies were investigated by both enzyme-linked im-
munosorbent assay (ELISA) and Western blot methodology.
Results. Glomerular deposits of SPE B were demonstrated
in 12/17 APSGN biopsies, and 2 cases were borderline; circu-
lating antibodies were found in all instances (53/53 patients).
Glomerular deposition of GAPDH was detected in 1/17 biop-
sies, and 2 cases were borderline; circulating antibodies were
found in 5/47 patients. In 31 control biopsies, only weak stain-
ing for each antigen was found in 2 cases.
Conclusion. In this study, glomerular deposits of and anti-
body response to zymogen/SPE B are more consistently present
in APSGN than deposits and antibody response to GAPDH.
Zymogen/SPE B is likely to be the major antigen involved in
the pathogenesis of most cases of APSGN.
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Acute post-streptococcal glomerulonephritis
(APSGN) is a nonsuppurative complication of in-
fection by group A streptococci. An immune complex
pathogenesis has been widely accepted since the land-
mark studies of Schick in 1907 [1], and the proposal
that there are “nephritogenic” streptococcal strains was
advanced more than half a century ago [2, 3]. How-
ever, the nature of the putative streptococcal antigen
responsible for acute glomerulonephritis has remained
elusive. Initial investigations centered on the M protein
[4], but the growing numbers of so-called “nephritogenic
M proteins,” (identified from streptococci isolated from
patients with glomerulonephritis), contrasted with the
notion of a single nephritogen conferring long-lasting
immunity, a concept anchored in the time-honored ob-
servation that repeated attacks of APSGN are extremely
rare. A series of subsequent investigations attempted to
identify the relevant antigen in kidney biopsies based on
their recognition by fluorescein-labeled immunoglobulin
fractions from convalescent sera [5, 6]. The conclusions
drawn from the latter series of studies are open to
question because: (1) it has been demonstrated that
serum rheumatoid factor activity is present in APSGN
[7, 8] and, consequently, immunoglobulin with anti-
human immunoglobulin G (IgG) reactivity present
in post-acute sera could have bound to glomerular
immunoglobulin deposits; and (2) late-stage sera contain
a rather wide spectrum of antibody specificities to
streptococcal components.
In the last decade, 2 well-characterized antigens have
attracted most attention: a secreted cationic cysteine pro-
teinase, also found in precursor form, the streptococcal
exotoxin B (zymogen, SPE B) [9–11], and a plasmin-
binding membrane receptor, the glyceraldehyde phos-
phate dehydrogenase (NAPlr/Plr, GAPDH) [12, 13].
These 2 antigens have been found within glomerular de-
posits in renal biopsy sections of APSGN patients [9–13]
and, in addition, are reported to induce an antibody re-
sponse characteristic for streptococcal infections causing
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nephritis [13, 14]. However, previous investigations have
always evaluated these potential nephritogens indepen-
dently. The present work reports back-to-back evaluation
of GAPDH/Plr and SPE B/Zymogen in the same biopsy
and serum specimens of APSGN patients, allowing di-
rect comparison of the consistency of positive findings,
and thereby contributing to clarification of the issue of
streptococcal nephritogenicity.
METHODS
Patients and samples
Frozen renal biopsy specimens from 17 patients with
verified APSGN, 31 control renal biopsies from non-
APSGN patients, and 4 normal kidney sections were
collected from the renal pathology archives of 3 institu-
tions [Department of Nephrology, Universidad Austral,
Valdivia, Chile (APSGN N = 9); Renal Service, Hospital
Universitario, Maracaibo, Venezuela (APSGN N = 4);
and The Institute of Pathology, Basel, Switzerland
(APSGN N = 4)]; for details see Results section. Biopsy
material from a case of APSGN that had been embedded
in LR-White resin (see below) was available for immuno-
electronmicroscopy.
Serum samples obtained 2 to 4 weeks after the be-
ginning of acute nephritis were available from a total of
53 cases of verified APSGN (including 6 of the biopsied
patients), and 14 controls of comparable age and having
no evidence of recent streptococcal infection. Serum sam-
ples were obtained from APSGN patients in Valdivia (15
samples), Maracaibo (34 samples), and Basel (4 samples)
(see Table 2).
Preparation of streptococcal extracellular zymogen/
cysteine proteinase
A b-hemolytic group A streptococcal strain (Mar-2),
isolated from a throat swab of a child with veri-
fied APSGN was used. The streptococcus was precul-
tured in 200 mL of brain-heart infusion (CM225,
Oxoid) at pH 7.0, 37◦C with shaking. When bacterial
growth had entered the logarithmic phase, this preculture
was transferred into a fermenter (Applikon, Schiedam,
Holland) containing 1800 mL of brain-heart infusion
(supplemented with 1% glucose) at 37◦C with stirring.
During growth, the pH was allowed to sink to a value of
6.0, where it was maintained by addition of 1N NaOH
containing 1% glucose. The initial culture at pH 7.0
allowed good growth, whereas production of zymogen
is known to be enhanced under acidic conditions [15].
When the culture reached the stationary phase, sodium
tetrathionate was added to a concentration of 1 mmol/L,
this reversibly inhibited conversion of zymogen into the
active proteinase form. Culture supernatants were har-
vested by centrifugation at 6000g for 30 minutes and
subsequently concentrated 100- to 500-fold by positive
pressure ultrafiltration in an Amicon cell using an YM10
membrane (Millipore, Billerica, MA, USA). Presence
of zymogen/proteinase in the concentrated supernatants
was confirmed by double diffusion agar gel analysis
against specific polyclonal rabbit antiserum. Further pu-
rification was performed chromatographically: concen-
trated supernatants were dialyzed against 3.5 mmol/L
MES buffer and applied to a Mono-S caption exchange
column (1 mL bed volume) (Amersham-Pharmacia,
Freiburg, Germany). A gradient of 3.5 to 250 mmol/L
MES buffer was run in Fast Protein Liquid Chromatog-
raphy (FPLC) system and fractions were examined in
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) under nonreducing conditions. Pro-
tein concentrations were measured by the method of
Bradford [16].
Preparation of streptococcal glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH)
The protein was prepared along the lines described by
Pancholi and Fischetti [17]. The streptococcal strain Mar-
2 was first grown in 100 mL Todd-Hewitt medium (CM
189, Oxoid) at 37◦C for 16 hours; this culture was then
added to 500 mL of fresh medium and cultured for a fur-
ther 18 hours with mild shaking. Bacteria were harvested
by centrifugation at 10,000g for 30 minutes, washed twice
in 50 mmol/L sodium acetate buffer, pH 5.5, and then
suspended in the same buffer containing 20% sucrose
and 5 mmol/L EDTA. Mutanolysin (120 U/mL) (M-9901,
Sigma, Taufkirchen, Germany) was added and incubated
for 90 minutes at 37◦C with slow stirring. The resulting
protoplasts were removed by centrifugation at 15,000g
for 30 minutes, the supernatant was dialyzed against 25
mmol/L Tris/HCl + 5 mmol/L EDTA buffer, pH 8.5, and
then concentrated by ultrafiltration in an Amicon cell us-
ing YM-10 membranes (Millipore). The concentrated ex-
tract was separated by ion-exchange chromatography on
a Mono-Q anion-exchange column (1 mL bed volume)
in an FPLC system (Amersham-Pharmacia, Freiburg,
Germany). The sample was applied in 25 mmol/L
Tris/HCl buffer, pH 8.5, bound proteins were eluted by
applying a linear NaCl gradient from 0 to 1 mol/L, 1 mL
fractions were collected, and tested in SDS-PAGE and
immunoblot.
SDS-PAGE and immunoblotting
Proteins were separated in discontinuous SDS-PAGE
(12.6% polyacrylamide gel) according to the method of
Laemmli [18], and stained with Coomassie blue. For im-
munoblotting, separated proteins were transferred elec-
trophoretically from the gel to polyvinylidene difluoride
membranes (PVDF; Immobilon-P, Millipore). The blot-
ted membranes were probed with test serum samples
diluted as required in blocking buffer [10% skimmed
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milk in phosphate-buffered saline (PBS)], washed, incu-
bated for 1 hour with the appropriate second antibody
(peroxidase-labeled antihuman IgG, antirabbit IgG, an-
timouse IgG, or anti-guinea pig IgG; Jackson Dianova,
Hamburg, Germany) and developed with DAB substrate.
N-terminal sequencing of proteins
Following SDS-PAGE of extracts and transfer to Im-
mobilon PVDF membranes, bands selected after light
staining with amido black were cut out for sequencing.
The samples were analyzed in a gas-phase sequencer
(model 477A; Applied Biosystems, Foster City, CA,
USA), with online identification of the amino acid deriva-
tives (model 120A) conducted according to the manufac-
turer’s recommendations.
Analysis of streptococcal antigens
Zymogen/cysteine proteinase (SPE B). Under the cul-
ture conditions chosen, the extracellular cysteine pro-
teinase in precursor form (zymogen) was the major
extracellular protein secreted by the group A strepto-
coccal strain used. The precursor zymogen migrated as a
41 to 43 kD band which, under reducing conditions, auto-
converted to a 28 to 30 kD band, representing the active
cysteine protease. The purity of the preparation obtained
by ion-exchange chromatography was >95%, as judged
from Coomassie blue–stained SDS-PAGE gels.
The N-terminal sequence of the zymogen fraction
was determined from a PVDF membrane containing
the transferred protein. It is shown aligned with the se-
quence of the N-terminal end of streptococcal pyrogenic
exotoxin B precursor obtained from the Swissprotein
database. There is complete agreement with 14/15 amino
acids.
The missing residue was presumably an arginine, which
is difficult to detect. Shading indicates identity of residues
(Box 1).
Zymogen Band 41/43 kD D Q N F A ? N E K E A K D S A
M N K K K L G I R L L S L L A L G G F V F A D Q N F A R N E K E A K D S A
SPE B Precursor/Swissprot)
Streptococcal GAPDH. Following the procedure de-
scribed above, a major protein fraction eluted from the
mono-Q column with 300 to 350mm NaCl. The main
component of this fraction was a 37 to 39 kD band in
SDS-PAGE. The N-terminal sequence of this band was
determined from a PVDF membrane containing trans-
ferred protein; it is shown aligned with GAPDH from
a number of sources. There is complete agreement with
16/17 amino acids of the streptococcal GAPDH identified
by Pancholi and Fischetti [17]. This band reacted very
strongly with 3 monoclonal antibodies to streptococcal
Plr in immune blot. The missing residue was presumably
an arginine, which is difficult to detect. Shading indicates
identity of residues (Box 2).
37/39 kD Band V V K V G I N G F G R I G ? L A F
39 kD SDH [17] V V K V G I N G F G R I G R L A F R R I Q N I E G
Escherichia coli GAPDH M T I V K V G I N G F G R I G R I V F R A A
Human GAPDH M G K V K V G I N G F G R I G R L V T R
Production of antibodies to streptococcal zymogen/
proteinase and GAPDH
Polyclonal antibodies to streptococcal zymogen were
raised in rabbits by 3 intramuscular immunizations with
500 lg of purified antigen in Freund’s Complete Adju-
vant, at 2-week intervals. The rabbits were bled 1 week
after the final injection. The gamma globulin fraction of
a selected antiserum to streptococcal zymogen, obtained
after repeated precipitation with 33% saturated ammo-
nium sulfate, was labeled with fluorescein isothiocyanate
(FITC; Nordic Immunologicals, Tilburg, Holland) [19]. A
small sample of the FITC-labeled guinea pig antiserum
to streptococcal cationic antigen used in an earlier study
[9] was also available for comparison.
Polyclonal antibodies to streptococcal GAPDH were
raised in rabbits and guinea pigs by 3 intramuscular in-
jections of purified antigen (rabbits 200 lg, guinea pigs
50 lg) in FCA, at 2-week intervals. The animals were
bled 1 week after the final injection.
Monoclonal antibodies to streptococcal GAPDH, ob-
tained from mouse hybridomas, were generously pro-
vided by Prof. M. Boyle (Department of Microbiology
and Immunology, Medical College of Ohio).
Analysis of antibody preparations
Immunization of rabbits with streptococcal zymogen
produced high titer antisera. The antisera gave a strong
precipitin line in double diffusion analysis and reacted
with both the zymogen (41/43 kD band), as well as the
active proteinase (28/30 kD band) in immune blot at di-
lutions up to 1:500,000 (Fig. 1, lane 11). The zymogen
is known to be antigenically superior to the active pro-
teinase [9]. The antisera did not react with the GAPDH
fraction used here when tested in immune blot (Fig. 1,
lane 8).
Immunization of rabbits with the GAPDH fraction in
FCA did not produce high titer antisera; only a weak
reaction in immune blot was seen at antibody dilutions
of 1:50. From experience, antisera with such titers are
not suitable for immunofluorescence (IF) studies. Further
immunization was done in guinea pigs, which produced an
antiserum giving a strong staining pattern in immune blot
at dilutions of up to 1:20,000 (Fig. 1, lane 7). When tested
on whole streptococcal cell lysate in immune blot, a strong
band was seen in the 37 to 39 kD region, corresponding to
streptococcal GAPDH(Plr)[17], weaker bands were seen
at 31, 43, and 94 kD, and these could not be identified with
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Fig. 1. Immunoblots of anti-zymogen/SPE B
and anti-GAPDH antibodies used. 1, 6, and
10 amido black stained strips of 3 antigen
preparations used (antigen indicated below
strips; GAS, group A streptococcus). The
monoclonal (2–4) and polyclonal (5) anti-
bodies to GAPDH/Plr(G) show varied band-
ing patterns. Lane 7 shows reaction of poly-
clonal anti-GAPDH/Plr on extract. Lane 9
shows reaction of 1 of 2 APSGN sera clas-
sified as showing a borderline reaction with
GAPDH. Lane 11 shows reaction of anti-
zymogen(Z)/proteinase(P)( = SPE B) anti-
serum with concentrated GAS culture su-
pernatant. Note lack of staining when poly-
clonal antibodies to zymogen/proteinase and
GAPDH are cross-tested (lanes 8 and 12, re-
spectively). M, marker.
certainty (Fig. 1, lane 5). This antiserum did not react with
zymogen/proteinase in immune blot (Fig. 1, lane 12). The
3 mAb to streptococcal Plr (GAPDH) all reacted strongly
with the 37 to 39 kD band in the GAPDH extract (similar
to lane 7, Fig. 1, results not shown); in addition, when
tested on whole cell lysates, a large number of weaker
bands was seen, and the banding pattern seen differed
between hybridomas (Fig. 1, lanes 2–4).
Immunohistology
Immunofluorescent staining was performed on 4-lm
frozen sections of renal biopsy specimens after fixation
in acetone at −20◦C. To reduce fading of FITC, sec-
tions were mounted in Citifluor AF-1 (Citifluor, Ltd.,
UK) and were viewed in a Zeiss Axiomat microscope
(Oberkochen, Germany). All biopsy specimens were
tested for deposition of human IgA, IgG, IgM, C3, and
fibrinogen using FITC-labeled commercial antisera.
Staining for streptococcal zymogen/proteinase (SPE
B) was done directly with an FITC-labeled polyclonal
rabbit antibody to zymogen. In selected biopsies, dou-
ble staining for human C3 and streptococcal zymo-
gen/proteinase was performed by sequential incubation
with the appropriate antibodies, labeled with TRITC and
FITC, respectively.
Staining for streptococcal GAPDH was done in-
directly: first antibody was guinea pig anti-GAPDH
diluted 1:40, followed by FITC-conjugated AffiniPure
anti-guinea pig IgG (H+L, minimal cross-reactivity to
human serum proteins; Jackson Dianova). Staining with
monoclonal antibodies to GAPDH was done indirectly;
the second antibody was FITC-conjugated AffiniPure
Rabbit anti-Mouse IgG (H+L, minimal cross reactivity
to human serum proteins; Jackson Dianova).
In all cases, appropriate controls were included (FITC-
labeled, non–cross-reacting rabbit antibodies or mAb of
the same isotype but with irrelevant specificities).
Positive staining was evaluated for intensity on a 0 to
3+ scale by 2 to 3 observers. Glomerular/extraglomerular
staining was recorded and the glomerular distribution
was defined as diffuse/focal/global and segmental. In
selected cases, where staining for zymogen/proteinase
and/or GAPDH was negative, IF staining with the ap-
propriate antisera was repeated on unfixed sections to
exclude the possibility that acetone fixation could have
impaired vital epitopes.
Immunoelectron microscopy
Immunoelectron microscopy was performed on ma-
terial embedded in LR-White resin (EMS) [20]. In
brief, small tissue blocks were fixed in 0.1% gluter-
aldehyde and 4% paraformaldehyde, dehydrated in
ethanol, and embedded in LR-White resin. Polymeriza-
tion was performed at 50◦C, and 80 nm sections were
mounted on nickel grids. Sections were stained with rab-
bit anti-zymogen antibody, diluted 1:10, followed by in-
cubation with gold-labeled (10 nm particles) antirabbit
IgG (AURION). Appropriate control staining was per-
formed, including omitting the first antibody and using
the anti-zymogen antibody after prior absorption with zy-
mogen. Incubation was also performed to detect human
IgG and C3. Sections were then contrasted with uranyl
acetate and lead citrate and viewed in a Phillips EM 300
microscope.
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Detection of circulating antibody to zymogen/
proteinase(SPE B) and GAPDH(Plr) by ELISA
and Western blot
ELISA testing was performed as follows: 100 lL of
antigen (contained 0.25 lg Zymogen/Proteinase or 0.5 lg
GAPDH) in carbonate buffer (pH 9.5, 0.5 mol/L) was
placed in each microtiter plate well, incubated for 1 hour
at room temperature (RT) and overnight at 4◦C. Then
the wells were washed 5 times with PBS containing
0.05% Tween 20. For testing, 100 mL of blanks or sam-
ples, diluted in PBS containing 2% Tween, was intro-
duced to the wells and incubated for 1 hour at RT be-
fore washing with 5 changes of PBS. Finally, 100 lL of
peroxidase-conjugated, affinity-purified goat antihuman
IgG was added for 1 hour at 37◦C and washed 5 times
with PBS. Then, 100 lL of substrate, o-phenyldiamine,
was added and incubated for 15 minutes, the reaction was
stopped with H2SO4, and the optical densities were read
at 490 nm in a microtiter plate reader. Serum samples
were tested in duplicate, and for positive controls, appro-
priate rabbit (anti-Zymogen/proteinase) and guinea pig
(anti-GAPDH) antibodies with the appropriate second
antibodies were used. For GAPDH, serum samples were
tested at a single dilution of 1:100, as then all extinction
values (lowest = 0.17, highest = 0.93) lay in the linear
range. In the case of Zymogen/Proteinase, at a dilution
of 1:100, the extinctions frequently reached saturation
levels; for this reason, sera were tested in doubling di-
lutions (final dilution 1:100,000), the titer being taken as
the highest dilution where the extinction still exceeded a
preset level (0.2).
Cut-off values were calculated from results obtained
with control sera; a value was considered to be elevated
when it exceeded the mean extinction/titer by ≥2SD.
Western blotting was performed as detailed above.
For detection of antibody to zymogen/proteinase, SDS-
PAGE of zymogen was performed under reducing con-
ditions to ensure that both forms were present. Serum
samples were diluted 1:100. Detection of antibody to
streptococcal GAPDH was performed in a similar
fashion. For positive controls, the appropriate specific
rabbit/guinea pig antibody, diluted 1:500, plus second
antibodies were run.
RESULTS
Patients
The 17 patients with APSGN included 9 children and
8 adults, 11 were male and 6 female, and ages ranged
from 5 to 70 years. All patients had a typical clinical
picture of APSGN, including hypertension and edema,
in addition to pathologic urinary findings (microscopic
hematuria, red blood cell casts, proteinuria) and low
serum complement. Pertinent aspects of the site and di-
Table 1. Clinical data of the 17 APSGN patients biopsied
Age range years 5–70
Sex (male:female) 11:6
High anti-streptococcal antibody titer/number tested
Anti-streptolysin O 11/17 (65%)
Anti DNAse B 11/14 (79%)
Anti-streptokinase 6/9 (67%)
Site of antecedent infection
Upper respiratory tract 8 (47%)
Skin 4 (24%)
Unknown 5 (29%)
Time interval before biopsy daysa 10–100
aTime between the first symptom and biopsy could only be ascertained in 13
cases. It ranged between 10 and 42 days, except in 1 patient biopsied after 100
days due to a protracted clinical course (see text).
agnosis of antecedent infection are shown in Table 1.
The diagnosis of antecedent streptococcal infection was
based on the finding of elevated titers of 1 or more
anti-streptococcal antibodies (anti-streptolysin-O, anti-
DNase-B, anti-streptozyme). The time point between
onset of renal symptoms and biopsy was reliably docu-
mented in 13 cases and ranged from 10 to 42 days, and
in a single case 100 days (the latter having an unusually
protracted course). There was no evidence of systemic
disease in any of the patients. The 31 control biopsies
were selected to include patients with a similar age and
sex distribution with other types of GN, without any ev-
idence of preceding streptococcal infection. These in-
cluded cases of IgA nephritis (N = 8), diffuse endocapil-
lary GN (N = 3), extracapillary proliferative GN (N = 2),
membranoproliferative GN (N = 1), membranous GN
(N = 5), segmental focal proliferative GN (N = 6), focal
segmental glomerulosclerosis GN (N = 3), diffuse pro-
liferative lupus-nephritis (N = 2), and a single case of
minimal lesions. All control biopsies had clear 1+ to 3+
deposits of 1 or more immunoglobulins and/or C3.
Detection of circulating antibody to zymogen/
proteinase(SPE B) and GADPH(Plr)
Zymogen/proteinase(SPE B). The center where the
patients were seen and the serum samples obtained, age,
sex, site of the antecedent infection, and the increased
anti-streptococcal antibody levels are shown in Table 2.
All 53 serum samples obtained from cases of verified
APSGN tested in immune blot against streptococcal zy-
mogen and proteinase showed a positive reaction, defined
as strong bands in 28 to 30 and 41 to 43 kD regions. In
ELISA, all 52 sera tested showed elevated titers of anti-
bodies (≥ mean + 2SD, Fig. 2A).
GAPDH(Plr). Serum samples from the 51/53 cases
of APSGN did not react in immune blot; in 2/53 cases, a
laddering pattern reminiscent of reactions with polysac-
charide antigens (e.g., LPS) was seen; one of these bands
corresponded to the 37 to 39 kD GAPDH band (defined
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Table 2. Data of patients in the serum studies
Parameter\center Valdivia Maracaibo Basel
(total samples) (N = 15) (N = 34) (N = 4)
Age range years 5–70 4–38 21–70
Sex (M:F) 9:6 24:10 3:1
Site of antecedent infection
Throat 2 (13%) 14 (41%) 2 (50%)
Skin 8 (53%) 12 (35%) 0 (0%)
Unknown 5 (33%) 8 (24%) 2 (50%)
Anti-streptococcal antibody titers
(N exceeding reference values)
Anti-streptolysin O 7 (47%) 12 (35%) 4 (100%)
AntiDNAse B 14 (93%) 24 (71%) 1/1 tested
Positive culture group 2/15 (13%) 2/31 (7%) 0/2 (0%)
A streptococci
(N positive/total tested)
by the guinea pig polyclonal and the mouse monoclonal
antibodies), and a borderline result was recorded (Fig. 1,
lane 9). In ELISA, only 3/47 sera available for testing
revealed an extinction value that exceeded the mean +
2SD of the control values (Fig. 2B).
Immunohistology—staining for zymogen/proteinase
(SPE B) and GAPDH in renal biopsy specimens. Poly-
clonal rabbit antibody to zymogen/proteinase (SPE B)
gave specific glomerular staining in 14 of 17 biopsies
(includes 2 borderline cases) from patients with APSGN
(Table 3); weak extraglomerular staining was seen in
4 cases in addition. The intensity of staining varied be-
tween specimens, between and within glomeruli; it was
graded between +/− and 1+ to 3+. In general, the
staining was in coarse granules and patches (Fig. 3A),
corresponding to mesangial areas and regions of the pe-
ripheral capillary walls; the distribution was diffuse within
glomeruli, either global or segmental. The 3 negative
biopsy specimens also remained negative when unfixed
sections were tested. Previous absorption of the anti-
serum with purified zymogen resulted in a drastic reduc-
tion in the intensity of fluorescence seen in all 14 positive
cases (Fig. 3B). The mean time elapsed between onset of
renal symptoms and biopsy was 14 days (range 10–24) in
biopsies with at least 1+ staining (single case where time
of onset to biopsy was 100 days was excluded from this
calculation), and was 29 days (range 15–42) in biopsies
showing borderline to negative staining. C3 was always
present, with or without zymogen/proteinase. A small
sample of the polyclonal guinea pig FITC-labeled anti-
body to streptococcal zymogen used in our earlier study
[9] was still available, and 9 biopsies were stained with
it; the results were essentially similar to those obtained
with the rabbit antisera detailed above. Staining with non-
immune rabbit antibody was negative in all cases tested
(17/17). The results of staining 31 renal biopsies from non-
ASPGN glomerulonephritis and in 4 normal kidneys with
anti-SPEB/zymogen are also shown in Table 3. In 2 cases,
1+ staining for zymogen/proteinase was seen; these pa-
tients had endocapillary GN and membranoproliferative
GN, respectively, morphology characteristic of postinfec-
tious GN, but a post streptococcal etiology could not be
established.
The results of staining for IgG, IgM, and C3 and
the correlation with zymogen/proteinase staining are
shown in Table 4. Clear-cut staining (>1+) was more
frequent in early biopsies with weak or negative stain-
ing for IgG and/or IgM, without reaching significance.
As can be seen, C3 was positive in all cases and im-
munoglobulins were always present in specimens positive
for zymogen/proteinase. Double staining for C3 and zy-
mogen/proteinase showed a high degree of colocalization
of these molecules (Fig. 3C).
Polyclonal guinea pig antibody to streptococcal
GAPDH(Plr) gave specific (1+) staining in 1/17 APSGN
biopsies, 2 biopsies gave borderline glomerular staining,
and 14/17 were negative (Table 1). Staining was repeated
on unfixed sections with similar results. On testing the
control biopsies, 29/31 were classified as negative and 2/31
showed 1+ glomerular staining (Table 1).
In addition to the polyclonal antibody to GAPDH, 3
mAb to this antigen were also available (supplied by M.
Boyle, Ohio). As detailed above, all 3 mAb, as well as the
polyclonal guinea pig antibody, reacted strongly with the
GAPDH preparation in immune blot. When tested on
sections from 4 samples of normal human kidney, 1 mAb
stained structures, resembling the nuclear membranes,
in normal renal tissue. The other 2 mAb also revealed
cross-reactivity and, in some renal biopsies, stained sur-
face antigens on infiltrating cells, both glomerular and
extraglomerular. The nature of the target antigen could
not be determined, but was unlikely to have been bac-
terial. For these reasons the 3 mAb were excluded from
further studies.
Immunoelectronmicoscopy on an LR-White embedded
APSGN specimen
This case showed immunogold staining for human C3
and IgG within the glomeruli that was especially abun-
dant within humps present in the glomerular capillary
wall (Fig. 4A and B). Gold particles, representing zy-
mogen/SPE B were also seen in the glomeruli, within
the mesangium, and along the basement membrane, and
were prominent within subepithelial humps; the quantity
was less than with IgG and C3 (Fig. 4C). The distribution
of C3 within humps was diffuse, whereas that of IgG and
zymogen/SPE B was more focal (Fig. 4D). Specificity of
these findings was tested by incubating sections with anti-
SPE B that had been previously absorbed with antigen,
or by omitting the first antibody and, in both instances, re-
vealed only sparsely distributed gold particles, indicating
the specificity of the reaction.
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Fig. 2. Scatter plots showing levels of anti-
bodies to (A) SPE B and (B) GAPDH in
APSGN patients compared to healthy con-
trols by ELISA. Upper limits of normal levels
(2SD above the mean) are 400 (anti-SPE B
antibody titer) and 0.56 (extinction GAPDH).
Positive control values: 1:500,000 (rabbit anti-
SPE B titer); 2.30 (guinea pig anti-GAPDH,
diluted 1:1,000); and 2.06 (monoclonal anti-
GAPDH, diluted 1:5000).
Table 3. Immunofluorescent staining for zymogen/SPE B and GAPDH in renal sections
Zymogen/SPE B GAPDH
Renal sample Positive [intensity] Borderline Negative Positive [intensity] Borderline Negative
APSGN
N = 17 12/17 2/17 3/17 1/17 2/17 14/17
[1+ (N = 5) (1+)
2+ (N = 6)
3+ (N = 1)]
Other GN
N = 31 2/31 0/31 29/31 2/31 0/31 29/31
[1+ (N = 2)] [1+ (N = 2)]
Normal kidney
N = 4 0/4 0/4 4/4 0/4 0/4 4/4
DISCUSSION
Acute post-streptococcal glomerulonephritis is a ma-
jor nonsuppurative sequel of infection with the group
A streptococcus. Both humoral and cell-mediated injury
triggered by antigen-antibody complex deposition, or for-
mation in the glomerulus is accepted as the cause of the
disease.
Attempts to identify antigenic streptococcal compo-
nents within glomerular structures were essentially un-
successful for several decades [4]. More recently, 2
well-defined antigenic moieties were reported to pro-
duce a specific antibody response, and have been found
within the glomeruli in biopsies of patients with APSGN.
These antigens are the plasmin receptor protein (Plr)
(identified as glyceraldehyde-3-phosphate dehydroge-
nase, GAPDH) [12, 13] and the extracellular strepto-
coccal cysteine proteinase (zymogen/proteinase, SPE B)
[9, 11, 14] To date, all these antigens have been studied in-
dependently; therefore, it is important to compare these
2 putative nephritogens, back-to-back, in the same serum
samples and renal biopsies of APSGN patients.
In the case of SPE B and the precursor zymogen, circu-
lating antibody was present in all of the sera from cases of
APSGN tested, often in very high titers. This is in line with
data from earlier studies in APSGN [11, 14] and group
A streptococcal infections in general [21]. In 2 extensive
studies, all group A isolates tested possessed the SpeB
gene [22, 23], and most appear to produce SPE B, which
explains why specific antibody to SPE B is so widespread.
In the case of streptococcal GAPDH (Plr), detection of
circulating antibody in APSGN was a rare event in our
hands; only 5/53 samples were positive in immunoblot
and ELISA. Streptococcal GAPDH proved to be a poor
immunogen in rabbits in our hands, and the antisera that
was used here was raised in the more sensitive guinea
pig species. There is considerable sequence homology be-
tween human and streptococcal GAPDH [17] that could
be responsible for a weak immune response. Two pre-
vious reports from Yoshizawa et al described Western
blot analysis of antibody to nephritis-associated plasmin
receptor (NAPlr) in sera from APSGN patients and con-
trol subjects. They reported positive reactions in Western
blot at frequencies of between 26% and 72% in controls
and 92% in APSGN cases [12, 13]; these latter authors did
not report results of ELISA tests. NAPlr shares a 98% se-
quence homology with Plr from GAS strain 64/14, which
is known to be streptococcal GAPDH [24]. We are not
aware of further studies on the immunogenicity of strep-
tococcal proteins of the Plr/GAPDH complex.
Polyclonal antisera to streptococcal zymogen/
proteinase stained glomerular deposits in 14/17 (82%)
of biopsies from patients with APSGN. Specificity of the
staining was tested by previous absorption of the anti-
serum with zymogen. The biopsies that were positive for
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Fig. 3. (A) Deposition of zymogen/SPE B in
glomerulus of APSGN biopsy stained with
FITC anti-SPE B, distribution is mesangial
and capillary. (B) Staining abolished by previ-
ous absorption of antisera with zymogen. (C)
Zymogen/SPE B (green) and C3 (red) show
colocalization (orange). (D) Light microscopy
of APSGN glomerulus showing extensive hy-
percellularity and deposits (PAS × 400).
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Fig. 4. Immunoelectronmicroscopy-immune
gold staining. (A) Staining for human C3,
extensive, diffuse staining in subepithelial
hump. (B) Staining for human IgG, scattered
staining in hump. (C) Staining for zymo-
gen/SPE B, patchy distribution of antigen
in hump. (D) Composite of A, B, and C,
gold particles replaced with colored spots, as
indicated, to allow better comparison of their
distribution. Areas shown correspond to the
same hump, but for technical reasons are not
consecutive serial sections. BM, basement
membrane; P, podocyte.
SPE B were performed a mean of 14 days after presumed
clinical onset, whereas in the borderline/negative cases,
the time elapsed averaged 29 days. The observation
that early biopsies are more likely to reveal antigen
deposits is in line with results of previous investigators
[4]. These data confirm 2 previous reports that SPE B
can be detected within glomerular deposits in APSGN
biopsies. Earlier, Vogt et al [9] described the localization
of a “cationic extra cellular streptococcal antigen” in
8/18 biopsies from APSGN patients; this antigen was
later confirmed to be SPE B or its zymogen precursor.
A sample of antiserum from this previous study was
still available and produced a similar staining pattern to
the antiserum used here in 8/9 APSGN biopsies tested.
More recently, Cu et al identified SPE B deposits in 12/18
APSGN biopsies using their own antibody preparations
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Table 4. Immunofluorescent staining for streptococcal antigens,
immunoglobulins, and C3 in renal sections (all renal biopsies positive for
zymogen/SPE B were also positive for IgG and/or IgM)
IgG IgM C3
[Intensity] [Intensity] IgG+M [Intensity]
Positive
zymogen/SPE B 10/14 11/14 14/14
(N = 14) [±/+ (N = 7) [±/+ (N = 9 7/14 [+ (N = 6
2+/3+ (N = 3)] 2+/3+ (N = 2)] 2+/3+ (N = 8)]
Negative
zymogen/SPE B 1/3 1/3 1/3 3/3
(N = 3) [± (N = 1)] [± (N = 1)] [+ (N = 1)
2+ (N = 2)]
[11]. Glomerular deposition of SPE B or the zymogen
precursor is clearly a prominent feature of APSGN.
The second streptococcal component studied here was
streptococcal GAPDH, a plasmin receptor protein (Plr)
[24]. When employing polyclonal antibody to streptococ-
cal GAPDH, detection of glomerular deposits of this anti-
gen in biopsies from ASPGN patients was a rather rare
event, compared to positive staining for zymogen/SPE
B. In fact, only 1/17 APSGN biopsies revealed mod-
est glomerular staining; 2 further cases were border-
line, and a similar result was seen in control biopsies,
where 2/31 showed modest glomerular staining. These re-
sults do indicate that our detection system for GAPDH
had adequate sensitivity. In contrast, in 2 other reports
[12, 13], 72% and 78%, respectively, of APSGN renal
biopsies revealed positive glomerular fluorescence when
stained with a polyclonal antibody to NAPlr, known to be
GAPDH. In this context, the possibility of cross-reaction
between constitutively expressed human GAPDH and
streptococcal GAPDH remains to be excluded. In these
latter reports, infiltrating leukocytes stained positive in a
ring-like pattern. No explanation for this interesting find-
ing was offered.
Antibodies from 3 different hybridomas, derived from
mice immunized with recombinant NAPlr, were gener-
ously made available to us. In Western blot, these mAb re-
acted strongly with GAPDH, but when tested with strep-
tococcal lysates revealed a broader range of reactivity.
When tested on renal biopsy specimens, serious problems
concerning specificity and interpretation of staining pat-
terns were encountered, as detailed above, and further
analysis was not done.
SPE B and C3 showed a high degree of colocalization
within glomeruli, as would be expected if both compo-
nents were contained in immune complexes. This con-
trasts with the results reported for NAPlr and C3 [13],
where the distributions of SPE B, C3, and IgG were es-
sentially different.
The single case of APSGN where renal tissue was
available for study by immuno-electronmicroscopy pro-
vided valuable information. Using immunogold labeling,
it was possible to confirm the presence of zymogen/SPE
B within the renal glomerulus and, in particular, within
subepithelial humps, together with IgG and C3. To our
knowledge, this is the only report of localization of a bac-
terial antigen within glomerular subepithelial humps in
APSGN; such humps are generally considered to be the
most typical lesion of the disease. Streptococcal zymo-
gen/SPE B are cationic molecules, and the distribution
seen within the glomerulus can be explained on the ba-
sis of charge interactions in this structure, as previously
elucidated in a series of experimental studies [25–28].
CONCLUSION
We confirmed the specific antibody response to
SPEB/zymogen in convalescent sera from APSGN pa-
tients and the renal deposition of this antigen in most re-
nal biopsies of patients with the disease. Antibody titers
to GAPDH were not different from the values in the gen-
eral population, and the demonstration of this antigen in
the kidney biopsies of APSGN patients was a rare event.
In trying to reconcile the discrepancies between our
results and those of Yoshizawa et al, it is worthwhile
to consider that both GAPDH and SPE B/zymogen are
widely distributed in streptococcal strains. Both SPE B
and streptococcal GAPDH can bind plasmin, and this
may be a common final pathway engaged by antigens in-
volved in APSGN [29]. Recently, these workers have re-
ported that streptococcal GAPDH was colocalized with
the plasmin receptor in APSGN biopsies [30].
The relatively low proportion of patients who develop
APSGN after group A streptococcal infections implies
that other factors, in addition to contact with a potentially
nephritogenic antigen, are required for development of
the disease. In this respect, our patients were selected
from different genetic and demographic backgrounds
than the patients of Yoshizawa et al, who studied a rel-
atively homogeneous population of Japanese patients. It
is conceivable that different streptococcal fractions are
capable of inducing acute nephritis in different ethnic
groups.
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